Keyphrases
Pulmonary Arterial Hypertension
49%
Pulmonary Hypertension
39%
Endostatin
29%
Binding Protein
26%
Growth Factor Binding
26%
Insulin-like
26%
Interleukin-6
25%
Disease Severity
22%
Disease Survival
18%
Pediatric Hypertension
18%
Hypertension Disease
17%
Disease Course
17%
Pediatric
13%
Congenital Heart Disease
12%
Right Ventricular Function
10%
Scleroderma
10%
Interleukin-6 Levels
9%
Clinical Outcomes
9%
Metabolism
9%
Johns Hopkins
9%
Neurodevelopmental Outcome
8%
Angiostatic
8%
Congenital Cardiac
8%
Cardiac Surgery
8%
Clinical Phenotype
8%
First Week of Life
8%
Preterm Infants
8%
Clinical Worsening
8%
Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO)
8%
Children with Down Syndrome
8%
Pediatric Congenital
8%
Congenital Heart
8%
Intravenous Prostanoid
8%
Environmental Exposure
8%
T-cell Receptor Excision Circles
8%
Inflammatory Biomarkers
8%
Cardiac Dysfunction
8%
Left Ventricular Assist Device
8%
Pediatric Heart Failure
8%
Cyclohexanone
8%
Kynurenine Pathway
8%
Randomized Clinical Trial
8%
Perinatology
8%
Novel Indicators
8%
Respiratory Disease
8%
Insulin-like Growth Factor 2 mRNA-binding Protein 2 (IGF2BP2)
8%
Resistin
8%
Growth Factors
7%
Insulin-like Growth factor-1
7%
Vascular Endothelial Growth Factor
7%
Medicine and Dentistry
Pulmonary Hypertension
100%
Pediatrics
54%
Endostatin
36%
Interleukin 6
35%
Biological Marker
32%
Polycyclic Aromatic Hydrocarbon
20%
Disease Course
17%
Somatomedin Binding Protein 2
17%
Disease Severity
13%
Persistent Truncus Arteriosus
12%
Prostacyclin
10%
Neonatal Infant
10%
Disease
9%
Heart Failure
9%
General Medicine
8%
Vasculotropin
8%
Extracorporeal Membrane Oxygenation
8%
Internal Medicine
8%
Left Ventricular Assist Device
8%
Interleukin 8
8%
Patient Care
8%
Respiratory Disease
8%
Pulmonary Vascular Disease
8%
Phenomics
8%
Hepatoma Derived Growth Factor
8%
Connective Tissue
8%
Heart Right Ventricle Failure
8%
T Lymphocyte Receptor
8%
Cyclohexanone
8%
Patient Care Planning
8%
Perinatology
8%
Metabolomics
8%
Diagnosis
7%
Lung Dysplasia
7%
Insulin-Like Growth Factor 1
6%
Lung Vascular Resistance
6%
Endothelial Cell
6%
Somatomedin
5%
Pulmonary Artery Smooth Muscle Cell
5%
Respiratory Distress Syndrome
5%
Interleukin 10
5%
Observational Study
5%
Hazard Ratio
5%
Pulmonary Artery
5%
Lung Artery Pressure
5%
Prematurity
5%
